Avalyn Pharma Expands Executive Team with Appointment of Howard M. Lazarus, MD, FCCP to the Role of Chief Medical Officer
Seattle, Aug. 07, 2023 (GLOBE NEWSWIRE) — Avalyn Pharma Inc., a clinical-stage biopharmaceutical company focused…
Seattle, Aug. 07, 2023 (GLOBE NEWSWIRE) — Avalyn Pharma Inc., a clinical-stage biopharmaceutical company focused…
MIAMI, Aug. 07, 2023 (GLOBE NEWSWIRE) — Longeveron Inc. (NASDAQ: LGVN) (“Longeveron” or “Company”), a…
MIAMI, Aug. 07, 2023 (GLOBE NEWSWIRE) — Longeveron Inc. (NASDAQ: LGVN) (“Longeveron” or “Company”), a…
Company to host an investor conference call and webcast at 4:30pm EDT NEW YORK, Aug….
Company to host an investor conference call and webcast at 4:30pm EDT NEW YORK, Aug….
Conference Call and Webcast Scheduled for Wednesday, August 16th at 8:30 am Eastern Time YAVNE,…
Conference Call and Webcast Scheduled for Wednesday, August 16th at 8:30 am Eastern Time YAVNE,…
Phase 1 trial initiation anticipated Q3 2023; Topline results expected in 2H 2024 CARMEL, Ind.,…
Phase 1 trial initiation anticipated Q3 2023; Topline results expected in 2H 2024 CARMEL, Ind.,…
CAMBRIDGE, Mass., Aug. 07, 2023 (GLOBE NEWSWIRE) — Voyager Therapeutics, Inc. (NASDAQ: VYGR), a biotechnology company…
CAMBRIDGE, Mass., Aug. 07, 2023 (GLOBE NEWSWIRE) — Voyager Therapeutics, Inc. (NASDAQ: VYGR), a biotechnology company…
— Reimbursed early access program allows for patients with hypothalamic obesity in France to receive…
— Reimbursed early access program allows for patients with hypothalamic obesity in France to receive…
BUFFALO, N.Y., Aug. 07, 2023 (GLOBE NEWSWIRE) — 22nd Century Group, Inc. (Nasdaq: XXII), a…
BUFFALO, N.Y., Aug. 07, 2023 (GLOBE NEWSWIRE) — 22nd Century Group, Inc. (Nasdaq: XXII), a…
Single nucleotide polymorphism (SNP) analysis module and interpretation of plasmids now available Added reporting customized…
Single nucleotide polymorphism (SNP) analysis module and interpretation of plasmids now available Added reporting customized…
STOUGHTON, Mass., Aug. 07, 2023 (GLOBE NEWSWIRE) — Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading,…
STOUGHTON, Mass., Aug. 07, 2023 (GLOBE NEWSWIRE) — Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading,…
Preclinical data with APG777 demonstrate the potential for significantly improved dosing over standard of care,…